The phrase "adequate safety profile" is correct and usable in written English.
It can be used in contexts related to health, pharmaceuticals, or any field where safety assessments are relevant.
Example: "The new medication has been tested extensively and has shown an adequate safety profile in clinical trials."
Alternatives: "satisfactory safety profile" or "acceptable safety profile."
The technique is widely used in our practice, with high effectiveness and adequate safety profile.
The non-irritant and adequate safety profile under sun-exposed skin conditions of the nanomaterials and the emulsions qualified the products for clinical efficacy assays.
In conclusion, in this Phase 1 trial the AMA1-C1/Alhydrogel+CPG 7909 vaccine demonstrated an adequate safety profile and was highly immunogenic in malaria-naïve individuals.
As there is an urgent need for innovative protective vaccine strategies, we must identify and exploit the mechanisms that can facilitate or inhibit immunity to M. tuberculosis, while simultaneously maintaining an adequate safety profile.
Initiate phase III study: demonstrated efficacy signal in addition to adequate safety profile.
The decision to proceed with a phase III trial is formally outlined as follows: Initiate phase III study: demonstrated efficacy signal in addition to adequate safety profile.
Studies were limited to phase II and III randomised controlled trials (RCTs) of everolimus or temsirolimus reporting on cancer patients with adequate safety profiles.
In this study, MEDI-546 appeared to have an adequate safety and tolerability profile.
In this study, mavrilimumab given as a single, escalating intravenous dose (0.01 10.0 mg/kg) had an adequate safety and tolerability profile in subjects with mild to moderate RA.
This Phase 1 study of MEDI-546 at single (0.1 20.0 mg/kg) and multiple (0.3 5.0 mg/kg/week, 4 doses) IV doses had an adequate safety and tolerability profile in adults with SSc.
These trials were double-blind randomized controlled studies designed to allow adequate comparison of the safety profile of PsA-TT with that of 2 licensed vaccines; some of the results have been reported elsewhere [ 12].
